PL2217208T3 - Kompleks kwasu nukleinowego oraz kompozycja do dostarczania kwasu nukleinowego - Google Patents

Kompleks kwasu nukleinowego oraz kompozycja do dostarczania kwasu nukleinowego

Info

Publication number
PL2217208T3
PL2217208T3 PL08848047T PL08848047T PL2217208T3 PL 2217208 T3 PL2217208 T3 PL 2217208T3 PL 08848047 T PL08848047 T PL 08848047T PL 08848047 T PL08848047 T PL 08848047T PL 2217208 T3 PL2217208 T3 PL 2217208T3
Authority
PL
Poland
Prior art keywords
nucleic acid
delivery composition
complex
acid complex
acid delivery
Prior art date
Application number
PL08848047T
Other languages
English (en)
Inventor
Hirofumi Takeuchi
Yuichi Tozuka
Yasuyuki Hira
Hidekazu Toyobuku
Original Assignee
Otsuka Pharma Co Ltd
Hirofumi Takeuchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Hirofumi Takeuchi filed Critical Otsuka Pharma Co Ltd
Publication of PL2217208T3 publication Critical patent/PL2217208T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PL08848047T 2007-11-08 2008-11-06 Kompleks kwasu nukleinowego oraz kompozycja do dostarczania kwasu nukleinowego PL2217208T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007291317 2007-11-08
PCT/JP2008/070642 WO2009061003A2 (en) 2007-11-08 2008-11-06 Nucleic acid complex and nucleic acid delivery composition
EP08848047A EP2217208B1 (en) 2007-11-08 2008-11-06 Nucleic acid complex and nucleic acid delivery composition

Publications (1)

Publication Number Publication Date
PL2217208T3 true PL2217208T3 (pl) 2012-01-31

Family

ID=40303461

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08848047T PL2217208T3 (pl) 2007-11-08 2008-11-06 Kompleks kwasu nukleinowego oraz kompozycja do dostarczania kwasu nukleinowego

Country Status (27)

Country Link
US (1) US8338584B2 (pl)
EP (1) EP2217208B1 (pl)
JP (1) JP5340282B2 (pl)
KR (1) KR101567108B1 (pl)
CN (1) CN101854918B (pl)
AR (1) AR069224A1 (pl)
AT (1) ATE522201T1 (pl)
AU (1) AU2008325504B2 (pl)
BR (1) BRPI0819187A2 (pl)
CA (1) CA2704236C (pl)
CO (1) CO6280469A2 (pl)
CY (1) CY1112029T1 (pl)
DK (1) DK2217208T3 (pl)
ES (1) ES2369869T3 (pl)
HR (1) HRP20110698T1 (pl)
IL (1) IL205237A0 (pl)
MX (1) MX2010005094A (pl)
MY (1) MY149917A (pl)
NZ (1) NZ584841A (pl)
PL (1) PL2217208T3 (pl)
PT (1) PT2217208E (pl)
RU (1) RU2465009C2 (pl)
SI (1) SI2217208T1 (pl)
TW (1) TWI426922B (pl)
UA (1) UA97559C2 (pl)
WO (1) WO2009061003A2 (pl)
ZA (1) ZA201002845B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
CA2976966C (en) 2010-12-29 2021-11-09 F. Hoffmann-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
ES2732216T3 (es) 2012-03-15 2019-11-21 Acraf Polímeros catiónicos a base de glucógeno
JPWO2019131727A1 (ja) * 2017-12-27 2021-02-12 コニカミノルタ株式会社 医薬の評価方法
WO2025029927A1 (en) * 2023-07-31 2025-02-06 The Board Of Regents Of The University Of Texas System Lipid nanoparticle

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238537A (ja) * 1988-03-18 1989-09-22 Toyo Jozo Co Ltd 肝障害治療剤
JP3150266B2 (ja) * 1994-04-01 2001-03-26 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US6248566B1 (en) * 1994-09-13 2001-06-19 Ezaki Glico Co., Ltd. Glucan having cyclic structure and method for producing the same
JP3107358B2 (ja) 1994-09-13 2000-11-06 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5827697A (en) 1995-03-31 1998-10-27 Ezaki Glico Co., Ltd. Process for preparing glucans having a cyclic structure
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Hivコファクター抑制剤
PT1129064E (pt) 1998-11-12 2008-01-31 Invitrogen Corp Reagentes de transfecção
CA2465860A1 (en) * 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
RU2289585C2 (ru) * 2002-02-04 2006-12-20 Корикса Корпорейшн Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
AU2003299531A1 (en) * 2002-08-05 2004-06-07 University Of Massachusetts Compounds for modulating rna interference
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons

Also Published As

Publication number Publication date
CA2704236A1 (en) 2009-05-14
PT2217208E (pt) 2011-11-08
KR20100092007A (ko) 2010-08-19
AR069224A1 (es) 2010-01-06
TW200927175A (en) 2009-07-01
RU2010123168A (ru) 2011-12-20
AU2008325504B2 (en) 2013-03-07
CY1112029T1 (el) 2015-11-04
EP2217208A2 (en) 2010-08-18
SI2217208T1 (sl) 2011-11-30
EP2217208B1 (en) 2011-08-31
WO2009061003A2 (en) 2009-05-14
US20100305190A1 (en) 2010-12-02
JP2011504457A (ja) 2011-02-10
AU2008325504A1 (en) 2009-05-14
UA97559C2 (uk) 2012-02-27
ES2369869T3 (es) 2011-12-07
MX2010005094A (es) 2010-05-27
CA2704236C (en) 2015-09-15
WO2009061003A3 (en) 2010-05-27
CN101854918A (zh) 2010-10-06
ZA201002845B (en) 2011-07-27
CO6280469A2 (es) 2011-05-20
CN101854918B (zh) 2012-11-28
BRPI0819187A2 (pt) 2015-05-05
NZ584841A (en) 2011-12-22
IL205237A0 (en) 2010-11-30
DK2217208T3 (da) 2011-10-10
MY149917A (en) 2013-10-31
HK1142278A1 (en) 2010-12-03
HRP20110698T1 (hr) 2011-10-31
JP5340282B2 (ja) 2013-11-13
TWI426922B (zh) 2014-02-21
ATE522201T1 (de) 2011-09-15
RU2465009C2 (ru) 2012-10-27
US8338584B2 (en) 2012-12-25
KR101567108B1 (ko) 2015-11-06

Similar Documents

Publication Publication Date Title
IL202345A0 (en) Nucleic acid nanoparticles and uses therefor
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
IL207569A0 (en) Compositions and methods for drug delivery
IL213365A (en) Imidazopyrazine and their pharmaceutical preparations
IL228817A0 (en) Pharmaceutical compounds
IL201420A0 (en) Nucleic acid enzymes and complexes and methods for their use
EP2116238A4 (en) Amino acid composition
EP2349550A4 (en) SYSTEM FOR MIXING AND DISTRIBUTING MULTIPLE COMPONENTS
IL195764A0 (en) Compositions and methods for drug delivery
PL2373675T3 (pl) Reagenty funkcjonalizujące tiole oraz ich zastosowania
PL394605A1 (pl) Trwała złożona kompozycja farmaceutyczna
GB0717376D0 (en) Composition and manufacture thereof
GB0603160D0 (en) Nucleic acid
EP2268278A4 (en) PHARMACEUTICAL COMPOSITION
ZA201002845B (en) Nucleic acid complex and nucleic acid delivery composition
EP2245942A4 (en) COCOA AND SPIRULINE-CONTAINING COMPOSITION
IL201116A0 (en) Prompt nucleic acid delivery carrier composition
IL207734A0 (en) Pharmaceutical composition
PT2154144E (pt) Oligonucleotídeos e utilização dos mesmos
GB2464200B (en) Pharmaceutical composition
PL2236145T3 (pl) Kompozycja farmaceutyczna i lek złożony
GB0817969D0 (en) Pharmaceutical composition
EP2405001A4 (en) NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERING COMPOSITION
GB2461611B (en) Composition and use thereof
EP2236135A4 (en) STABLE PHARMACEUTICAL COMPOSITION